Literature DB >> 9345321

Serum leptin levels are associated with hyperinsulinemia independent of body mass index but not with visceral obesity.

H Kim-Motoyama1, T Yamaguchi, T Katakura, M Miura, Y Ohashi, Y Yazaki, T Kadawaki.   

Abstract

To examine the relationship between leptin levels and visceral obesity or plasma insulin levels, we studied serum leptin levels, fat distribution assessed by CT scan, and plasma insulin levels during 75 g oral glucose load in 100 Japanese men. Regression analysis adjusted by age and body mass index (BMI) showed leptin levels to be associated with visceral fat area(V)(p = 0.003), subcutaneous fat area(S)(p < 0.0001), and V + S(p < 0.0001), but not with V/S ratio(p = 0.897). By regression analysis adjusted by age, BMI, and V + S, serum leptin levels were still highly and positively correlated with plasma insulin levels during 75 g oral glucose load (p < 0.001), insulin resistance index(p < 0.001), and beta cell function index(p = 0.009) in homeostasis model assessment. These data suggest that hyperinsulinemia, but not visceral obesity, may be regulators of serum leptin levels independent of BMI.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345321     DOI: 10.1006/bbrc.1997.7329

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing's syndrome compared to controls matched for body mass index.

Authors:  U Schafroth; K Godang; T Ueland; J P Berg; J Bollerslev
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 5.467

2.  Plasma soluble leptin receptor levels are associated with pancreatic β-cell dysfunction in patients with type 2 diabetes.

Authors:  Tomoaki Morioka; Masanori Emoto; Yuko Yamazaki; Masafumi Kurajoh; Koka Motoyama; Katsuhito Mori; Shinya Fukumoto; Atsushi Shioi; Tetsuo Shoji; Masaaki Inaba
Journal:  J Diabetes Investig       Date:  2017-04-25       Impact factor: 4.232

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.